Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Lancet Infect Dis. 2023 May 10;23(9):1062–1071. doi: 10.1016/S1473-3099(23)00139-1

Table 2:

Immune response for poliovirus types 1, 2, and 3 by study group in the modified intention-to-treat population

nOPV2 only group (n=244) nOPV2 plus bOPV group (n=246) bOPV only group (n=246)

Poliovirus type 1
Immune response at the age of 10 weeks after one dose 2 (1%; 0–3) 191 (78%; 72–83) 193 (78%; 73–83)
Cumulative immune response by the age of 14 weeks after two doses 10 (4%; 2–7) 227 (92%; 88–95) 229 (93%; 89–96)
Cumulative immune response by the age of 18 weeks after three doses 20 (8%; 5–12) 240 (98%; 95–99) 240 (98% [95–99)
Poliovirus type 2
Immune response at the age of 10 weeks after one dose 156 (64%; 58–70) 72 (29%; 24–35) 0 (0%; 0–2)
Cumulative immune response by the age of 14 weeks after two doses 209 (86%; 81–90) 159 (65%; 58–70) 5 (2%; 1–5)
Cumulative immune response by the age of 18 weeks after three doses 225 (92%; 88–95) 193 (78%; 73–83) 20 (8%; 5–12)
Poliovirus type 3
Immune response at the age of 10 weeks after one dose 3 (1%; 0–4) 160 (65%; 59–71) 148 (60%; 54–66)
Cumulative immune response by the age of 14 weeks after two doses 6 (2%; 1–5) 216 (88%; 83–91) 212 (86%; 81–90)
Cumulative immune response by the age of 18 weeks after three doses 8 (3%; 2–6) 233 (95%; 91–97) 231 (94%; 90–96)

Data are the number of vaccine responders (% [95% CI]). bOPV=bivalent oral poliovirus vaccine. nOPV2=novel oral poliovirus vaccine type 2.